AR120222A1 - Anticuerpos dirigidos a flt3 y uso de los mismos - Google Patents

Anticuerpos dirigidos a flt3 y uso de los mismos

Info

Publication number
AR120222A1
AR120222A1 ARP200102839A ARP200102839A AR120222A1 AR 120222 A1 AR120222 A1 AR 120222A1 AR P200102839 A ARP200102839 A AR P200102839A AR P200102839 A ARP200102839 A AR P200102839A AR 120222 A1 AR120222 A1 AR 120222A1
Authority
AR
Argentina
Prior art keywords
flt3
proteins
antibodies directed
pharmaceutical compositions
cell
Prior art date
Application number
ARP200102839A
Other languages
English (en)
Inventor
Thomas J Mquade
Zong Sean Juo
Asya Grinberg
Ann F Cheung
Gregory P Chang
Hemanta Baruah
Original Assignee
Dragonfly Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=75538063&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR120222(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dragonfly Therapeutics Inc filed Critical Dragonfly Therapeutics Inc
Publication of AR120222A1 publication Critical patent/AR120222A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Proteínas con dominios variables de cadena ligera y cadena pesada del anticuerpo que se pueden emparejar para formar un sitio de unión a antígenos dirigido a FLT3 en una célula, composiciones farmacéuticas que comprenden dichas proteínas y métodos terapéuticos que usan dichas proteínas y composiciones farmacéuticas, inclusive para el tratamiento del cáncer.
ARP200102839A 2019-10-15 2020-10-14 Anticuerpos dirigidos a flt3 y uso de los mismos AR120222A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962915120P 2019-10-15 2019-10-15

Publications (1)

Publication Number Publication Date
AR120222A1 true AR120222A1 (es) 2022-02-02

Family

ID=75538063

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200102839A AR120222A1 (es) 2019-10-15 2020-10-14 Anticuerpos dirigidos a flt3 y uso de los mismos

Country Status (15)

Country Link
EP (1) EP4045537A1 (es)
JP (1) JP2022551757A (es)
KR (1) KR20220082882A (es)
CN (1) CN115348972A (es)
AR (1) AR120222A1 (es)
AU (1) AU2020366000A1 (es)
BR (1) BR112022006817A2 (es)
CA (1) CA3153801A1 (es)
CL (1) CL2022000927A1 (es)
CO (1) CO2022004743A2 (es)
IL (1) IL292259A (es)
MX (1) MX2022004291A (es)
PE (1) PE20221256A1 (es)
TW (1) TW202124449A (es)
WO (1) WO2021076554A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4291233A1 (en) * 2021-02-10 2023-12-20 Wugen, Inc. Polypeptides and their use in treatment of disease
IL310862A (en) * 2021-08-16 2024-04-01 Hemogenyx Pharmaceuticals Llc Antibodies against FLT3, chimeric antigen receptors, chimeric antigen receptor T cells and methods of use
WO2023105087A1 (en) * 2021-12-10 2023-06-15 Tubulis Gmbh Novel flt3 antibodies and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof in combination with tyrosine kinase inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR071891A1 (es) * 2008-05-30 2010-07-21 Imclone Llc Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
NL2014108B1 (en) * 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
US20180312592A1 (en) * 2015-07-16 2018-11-01 Cellerant Therapeutics, Inc. Cysteine-substituted immunoglobulins

Also Published As

Publication number Publication date
EP4045537A1 (en) 2022-08-24
WO2021076554A8 (en) 2022-04-21
IL292259A (en) 2022-06-01
AU2020366000A1 (en) 2022-05-12
PE20221256A1 (es) 2022-08-16
JP2022551757A (ja) 2022-12-13
MX2022004291A (es) 2022-05-10
WO2021076554A1 (en) 2021-04-22
BR112022006817A2 (pt) 2022-07-05
KR20220082882A (ko) 2022-06-17
TW202124449A (zh) 2021-07-01
CA3153801A1 (en) 2021-04-22
CN115348972A (zh) 2022-11-15
CO2022004743A2 (es) 2022-07-08
CL2022000927A1 (es) 2022-10-28

Similar Documents

Publication Publication Date Title
CL2023002105A1 (es) Dominios variables de anticuerpo que se dirigen a cd33 y sus usos
AR120222A1 (es) Anticuerpos dirigidos a flt3 y uso de los mismos
CO2020010345A2 (es) Dominios variables de anticuerpos que se dirigen al receptor nkg2d
CY1120849T1 (el) Αντισωμα που συνδεεται σε ανθρωπινο cd3
CO2018011195A2 (es) Composiciones que comprenden una coformulación de anticuerpos anti-pd-l1 y anti-ctla-4
MX2020013169A (es) Conjugados de camptotecina.
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
CL2018003758A1 (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso. (divisional solicitud 201800458)
BR112018014760A2 (pt) anticorpos anti-ror1, anticorpos biespecíficos para ror1 x cd3 e métodos de uso dos mesmos
CU20170169A7 (es) Anticuerpos de factor xi
UY35964A (es) Anticuerpos humanos para pd?1
CL2016002667A1 (es) Anticuerpos anti-rnf43 novedosos y métodos para su uso
CL2021002586A1 (es) Anticuerpos de cadena pesada que se unen al psma
PE20150646A1 (es) Metodos de tratamiento de una tauopatia
AR108468A1 (es) POLIPÉPTIDOS DE FUSIÓN CD40L-Fc Y MÉTODOS DE USO DE LOS MISMOS
CL2020002539A1 (es) Anticuerpos multiespecíficos anti-hla-g y utilización de los mismos
PE20161210A1 (es) Anticuerpos anti-mcam y metodos de uso asociados
EA202091888A1 (ru) Вариабельные домены антител, нацеленные на рецептор nkg2d
ECSP21090414A (es) Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
ECSP21052193A (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r
CO2019003759A2 (es) Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos
CO2021001410A2 (es) Proteínas de unión multiespecíficas que se unen a bcma, nkg2d y cd16 y métodos de uso
ECSP20082970A (es) Conjugados de fármaco y anticuerpo anti-sez6 y métodos de uso
MX2022013882A (es) Anticuerpos dirigidos contra el miembro a de la familia de dominios de lectina tipo c 12 (clec12a) y uso de los mismos.
BR112023002150A2 (pt) Anticorpos direcionando egfr e uso dos mesmos